A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.

Journal Article (Clinical Trial;Journal Article)

Gemcitabine is a pyrimidine analog that is active in patients with aggressive lymphomas and Hodgkin disease. This study assessed tumor response in patients with previously treated follicular or small lymphocytic non-Hodgkin lymphoma. This was a 2-stage phase II trial with the first stage requiring 2 of 13 responses to proceed to the second stage. Gemcitabine was given as a single agent to patients with previously treated follicular or small lymphocytic lymphomas. Gemcitabine was administered at 1250 mg/m2 over 30 minutes on days 1 and 8 of a 21-day cycle for a maximum of 6 cycles. Thirteen patients were treated with 1 to 6 cycles of chemotherapy. Two patients experienced grade 4 toxicity with neutropenia. No grade 4 nonhematologic toxicity was seen. There was 1 partial response and 8 patients (61%) had either minimal response or stable disease. Single-agent gemcitabine administered at this dose and schedule produced 1 partial remission and half the patients had stable disease. However, the study had to be stopped early because of lack of meaningful response.

Full Text

Duke Authors

Cited Authors

  • Ganjoo, KN; Robertson, MJ; Fisher, W; Jung, S-H; McClean, J; Huh, SY; Bufill, J; Williams, S; Cripe, LD

Published Date

  • April 2005

Published In

Volume / Issue

  • 28 / 2

Start / End Page

  • 169 - 172

PubMed ID

  • 15803012

Electronic International Standard Serial Number (EISSN)

  • 1537-453X

Digital Object Identifier (DOI)

  • 10.1097/01.coc.0000144812.74663.d0


  • eng

Conference Location

  • United States